Breaking News
Sort by:
Top Post
Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious […]
Former Vaccine Chief Returns As NHS Prepares For Winter
NHS chief executive Amanda Pritchard today announced that former vaccine chief Dr Emily Lawson is returning […]
NHS Opens Online Covid-19 Vaccination Bookings For 12-15 Year Olds
Parents will be able to book covid-19 vaccinations online for their 12-15 year old children […]
UK Government Secures Groundbreaking COVID-19 Antivirals
Thousands of vulnerable patients could be taking ground-breaking COVID-19 antivirals this winter after the government […]
Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration (FDA) […]
NHS Delivers Over Three Million COVID Boosters in First Month
More than three million top up COVID-19 jabs have been delivered in just four weeks, […]
Lateral Flow Tests to be Introduced for Vaccinated International Arrivals
Eligible fully vaccinated passengers arriving in England from countries not on the red list can […]
Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Topelia Australia Launches US$25M Series A Call for COVID-19 ATT Ziverdox
Topelia Australia, a biotech company established to commercialise a novel ATT treatment for Australians in […]
AZD7442 Reduced Risk of Developing Severe COVID-19 or Death in TACKLE Phase III Outpatient Treatment Trial
Positive high-level results from the TACKLE Phase III COVID-19 treatment trial showed AstraZeneca‘s AZD7442, a […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more